Overcoming resistance to anti-PD-1/PD-L1 therapy in cancer
Lijun Li, Yanbin Zhao, Xinhong Shi, Xiaotian Guo, Xiaoxin Zhang, Guangrui Li, Qingwei Meng, Minghui Zhang, Mingzhu Yin · 2026
Read Overcoming resistance to anti-PD-1/PD-L1 therapy in cancer by Lijun Li, Yanbin Zhao, Xinhong Shi, Xiaotian Guo, Xiaoxin Zhang, Guangrui Li, Qingwei Meng, Minghui Zhang, Mingzhu Yin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13244269.txt.
Description
Lijun Li and co-authors review, in a 2026 paper, how to beat cancer's resistance to a leading class of immune drugs. These checkpoint drugs transformed care, with dozens approved in a decade, yet only a minority of patients gain lasting benefit. The review maps where the drugs work alone and where they stall.
Pairing targets is the main escape route. Combos against blood vessel growth, a second checkpoint, and a third brake molecule are weighed, with one dual-target drug singled out for its trial success. Wider angles include reshaping the tumor's neighborhood and tuning the body's microbes and hormones. The authors frame a precision plan for combo design.
Catalog record
| CREATOR | Lijun Li, Yanbin Zhao, Xinhong Shi, Xiaotian Guo, Xiaoxin Zhang, Guangrui Li, Qingwei Meng, Minghui Zhang, Mingzhu Yin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |